The effect of nebivolol on the production of nitric oxide induced by bacterial lipopolysaccharide and peptidoglycan in mice

Fadi El-Rami, Hampartsoum Barsoumian, Joseph Simaan, Alexander M. Abdelnoor

.

DOI: 10.4236/ns.2010.212166                

Abstract

Nitric oxide (NO) plays a pivotal role in main- taining balance of physiological events in many systems including the autonomic, cardiovas- cular, hematological, and pulmonary systems. Lipopolysaccharide (LPS) and peptidoglycan (PGN), components of the outer cell membranes of Gram-negative bacteria and cell walls of Gram-positive bacteria respectively, are in- criminated in NO-induced septic shock. Ne- bivolol is a third generation β1- adrenoceptor blocker with a vasodilatory property attributed to enhanced availability of nitric oxide and re- duction of cellular oxidative stress through an unknown mechanism. The current study ex- plored the hypothesis that if nebivolol enhances the availability of NO, pretreatment with ne- bivolol may enhance production of NO in re- sponse to subsequent treatment with LPS and PGN, an observation that may have relevance in clinical septic shock. Groups of female BALB/c mice each containing 12 mice (6-8 weeks old) were injected intraperitoneally with LPS (30 µg/mouse), PGN (100 µg/mouse), nebivolol (0.25 µg/g, 0.35 µg/g, 0.7 µg/g), LPS and nebivolol (0.25 µg/g), LPS and nebivolol (0.35 µg/g), LPS and nebivolol (0.7 µg/g), PGN and nebivolol (0.25 µg/g), PGN and nebivolol (0.35µg/g). One group of mice was injected with saline and an- other served as control. Three mice from each group were bled 1, 3, 6 and 9 hours post-injec- tion, the blood was pooled and the nitrite serum levels, reflecting NO concentration, were de- termined using Greiss reagent. The following results were obtained: 1) Treatment with saline did not induce NO production; 2) LPS induced NO production to a maximal limit of 545% at 9 hours as compared to treatment with saline; 3) PGN did not induce NO production; 4) nebivolol at most doses and periods (7 out of 10 deter- minations) increased NO production over a range of 18-110% as compared to treatment with saline; 5) Nebivolol enhanced LPS-induced production of NO by 58% at a dose of 0.7 µg/gm at 9 hours. It is concluded that nebivolol in- duces NO production. At low doses nebivolol initially appeared to have a suppressive or no effect on NO production induced by LPS. In- crease in the dose of nebivolol resulted in augmentation of LPS-induced production of NO. PGN, in the dose tested, did not have an effect on NO production.

Keywords

Nebivolol; Peptidoglycan; Lipopolysaccharide; Nitric Oxide; β1- Adrenoceptor Blocker

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Furchgott, R.F., Zawadzki, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
[2]	Ignarro, L. (1990) Nitric Oxide: A novel transduction mechanism for transcellular communication. Hyper- tension, 16, 477-483.
[3]	Hobbs, A., Higgs, A. and Moncada, S. (1999) Inhibition of nitric oxide synthase as a potential therapeutic target. Annual Review Pharmacology Toxicology, 39, 191-220.
[4]	Maffei, A. and Lembo, G. (2009) Nitric oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease, 10, 1-11.
[5]	Falciani, M., Rinaldi, B. D., Agostino, B., Mazzeo, F., Rossi, S. and Nobili, B. (2001) Effects of nebivolol on human platelet aggregation. Journal of Cardiovascular Pharmacology, 38, 922-929.
[6]	Ignarro, J., Sisodia, M., Trinh, K., Bedrood, S., Wu, G., Wei, L. and Buga, G. (2002) Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide, 7, 83-90.
[7]	Mercanoglu, G., Safran, N., Gungor, M., Pamukcu, B., Uzun, H. and Sezgin, C. (2008) The effects of nebivolol on apoptosis in a rat infarct model. Circ J., 72, 660-670.
[8]	Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P. and Cook, S. (2007) Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovascular Drugs and Therapy, 21, 99-108.
[9]	Hancock, C.M. and Walsh, D.A. (2008) Modulation of pain in osteoarthritis: the role of nitric oxide. Clinical Journal of Pain, 24, 353-365.
[10]	Szabo, C. and Radi, R. (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nature Reviews Drug Discovery, 6, 662-680.
[11]	Mackenzie, I., Rutherford, D. and MacDonald, T. (2008) Nitric Oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Research & Therapy, 10, 2.
[12]	Guix, F., Uribesalgo, I., Coma, M. and Munoz, F. (2005) The physiology and pathophysiology of nitric oxide in the brain. Progress in Neurobiology, 76, 126-152.
[13]	Raetz, C.R.. (1990) Biochemistry of endotoxin. The Annual Review of Biochemistry, 59, 129-170.
[14]	Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nature Reviews Immunology, 4, 499-511.
[15]	Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., Huber, M., Kalis, C., Keck, S., Galanos, C., Freudenberg, M. and Beutler, B. (2005) CD14 is required for MyD88-inde- pendent LPS signaling. Nature Immunolog, 6, 565-570.
[16]	Kitchens, R.L., Thompson, P.A., O’Keefe, G.E. and Munford, R.S. (2000) Plasma constituents regulate LPS binding to, and release from, the monocyte cell surface. Journal of Endotoxin Research, 6, 477-482.
[17]	Mangrella, M., Rossi, F., Fici, F. and Rpssi, F. (1998) Pharmacology of nebivolol. Pharmacological Research, 38, 6.
[18]	Broeders, M., Doevendans, P.A. and Van Der Zee, R. (2000) Nebivolol: A third generation beta-blocker that augments vascular no release. Circulation, 102, 677-684.
[19]	Maffei, A., Pardo, A., Carangi, R., Lembo, G., Carullo, P., Poulet, R., Gentile, M. and Vecchione, G. (2007) Nebivolol induces Nitric Oxide release in the heart through inducible Nitric Oxide synthase activation. Hypertension, 50, 652- 656.
[20]	Weiss, R. (2006) Nebivolol: A novel beta-blocker with nitric Oxide-induced vasodilatation. Vascular Health and Risk Management, 2, 303-308.
[21]	Veverka, A. and Salinas, J. (2007) Nebivolol in treatment of chronic heart failure. Vascular Health and Risk Man- agement, 3, 647-654.
[22]	Agabiti-Rosei, E., Porteri, E. and Rizzoni, D. (2009) Arterial stiffness, hypertension, and rational use of nebivolol. Vascular Health and Risk Management, 5, 353-360.
[23]	Zanchetti, A. (2004) Clinical pharmacodynamics of ne- bivolol. Blood Pressure Supplies, 1, 17-32.
[24]	Gupta, S. and Wright, H.M. (2008) Nebivolol: A highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing Nitric Oxide. Cardiovascular Therapeutics, 26, 189-202.
[25]	Papademetriou, V. (2008) Beta blockers in management of hypertension: Focus on nebivolol. Expert Review of Cardiovascular Therapy, 6, 471-479.
[26]	Judy, W.M. Cheng, B.S. (2009) Nebivolol: A third-gen- eration P-Blocker for hypertension. Clinical Therapeu- tics, 31, 3.
[27]	Ladage, D., Brixius, K., Hoyer, H., Steingen, C., Wesseling, A. and Malan, D. (2006) Mechanisms underlying nebivolol-induced endothelial Nitric Oxide synthase activation in human umbilical vein endothelial cells. Clinical and Experimental Pharmacology and Physiology, 33, 720-724
[28]	Ignarro, J., Sisodia, M., Trinh, K., Bedrood, S., Wu, G., Wei, L. and Buga, G. (2002) Nebivolol inhibits vascular smooth muscle cell proliferation by Mechanisms involving Nitric Oxide but not cyclic GMP. Nitric Oxide, 7, 83-90.
[29]	Maffei, A. and Lembo, G. (2009) Nitric Oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease, 10, 1-11.
[30]	Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P. and Cook, S. (2007) Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovascular Drugs and Therapy, 21, 99-108.
[31]	Maffei, A., Vecchione, C., Aretini, A., Poulet, R., Bettarini, U. and Gentile, M.T. (2006) Characterization of nitric oxide release by nebivolol and its metabolism. American Journal of Hypertension, 19, 579-586.
[32]	Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C. and Ogawa, H. (2002) Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. The Journal of Clinical Investigation, 109, 1351-1359.
[33]	Tzemos, N., Lim, P.O. and MacDonald, T.M. (2001) Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double-blind, crossover study. Circulation, 104, 511-14.
[34]	MacMicking, J.D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D.S., Trumbauer, M., Stevens, K., Xie, Q.W., Sokol, K. and Hutchinson, N. (1997) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell, 8, 641-650.
[35]	Cobb, J.P. and Danner, R.L. (1996) Nitric oxide and septic shock. The Journal of the American Medical Association, 275, 1192-1196.
[36]	Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nature Reviews Immunology, 4, 499-511.
[37]	Bagchi, A., Herrup, E., Warren, E., Trigilio, J., Shin, H., Valentine, C. and Hellman, J. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. The Journal of Immunology, 178, 1164-1171.
[38]	Kawai, T., Adachi, O., Ogawa, T., Takeda, K. and Akira. S. (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122.
[39]	Kreutz, M., Ackermann, U., Hauschildt, S., Krause, S.W., Riedel, D., Bessler, W. and Andreesen, R. (1997) A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology, 92, 396-401.
[40]	Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Huffel, C.V., Du, X., Birdwell, D., Alejos, E., Silva, M. and Galanos, C. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 282, 2085-2088.
[41]	Guix, F., Uribesalgo, I., Coma, M. and Munoz, F. (2005) The physiology and pathophysiology of nitric oxide in the brain. Progress in Neurobiology ,76, 126-152
[42]	Manni, M. and Maestroni, G. (2008) Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: Involvement of β-adrenoceptors and relevance in inflamematory diseases. Brain, Behavior, and Immunity, 22, 80-88.
[43]	Fahmi, H., Ancuta, P. and Chaby, R. (1996) Preexposure of mouse peritoneal macrophages to lipopolysaccharide and other stimuli enhances nitric oxide response to secondary stimuli. Inflammation Research, 45, 347-356.
[44]	Ida, A.J., Giebelen, Masja, L., Mark, C.D., Joost, C.M., Meijers, M.L., Christian, D., Sonja, von A. and Tom van der P. (2008) Endogenous adrenergic receptors inhibit LPS-induced pulmonary cytokine release and coagulation. AJRCMB Articles in Press.
[45]	Arai, K., Wood, J.P. and Osborne, N.N. (2003) Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Research, 985, 176-86.
[46]	Palsson-McDermott, E. and O’Neill, L. (2004) Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology, 113, 153-162.
[47]	Dziarski, R. and Gupta, D. (2005) Peptidoglycan recognition in innate immunity. Journal of Endotoxin Research, 11, 304-310.
[48]	Dziarski, R. and Gupta, D. (2005) Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: A reevaluation. Infection and Immunity, 73, 5212-5216.